Kamada (NASDAQ:KMDA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the biotechnology company’s stock.

Kamada Trading Up 3.1 %

Shares of NASDAQ KMDA opened at $7.32 on Thursday. The stock has a market capitalization of $420.75 million, a PE ratio of 26.14, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99. The stock’s fifty day simple moving average is $7.08 and its two-hundred day simple moving average is $6.14. Kamada has a 12-month low of $4.74 and a 12-month high of $9.15.

Institutional Trading of Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Plato Investment Management Ltd purchased a new stake in shares of Kamada during the 3rd quarter valued at $117,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada during the 3rd quarter valued at $77,000. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the 4th quarter valued at $67,000. Geode Capital Management LLC lifted its holdings in shares of Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC lifted its holdings in shares of Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 6,850 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.